Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of “Buy” from Brokerages

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have received an average rating of “Buy” from the nine ratings firms that are covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $13.97.

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the company an “overweight” rating in a research report on Wednesday, March 12th. Wedbush reaffirmed an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Finally, Canaccord Genuity Group lowered their target price on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, March 13th.

Insider Buying and Selling at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 10,885 shares of the business’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total transaction of $37,335.55. Following the completion of the transaction, the chief executive officer now directly owns 430,931 shares in the company, valued at $1,478,093.33. The trade was a 2.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Large investors have recently added to or reduced their stakes in the business. Vestal Point Capital LP raised its holdings in shares of Voyager Therapeutics by 151.0% in the 4th quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock valued at $6,974,000 after acquiring an additional 740,000 shares in the last quarter. Farallon Capital Management LLC raised its stake in Voyager Therapeutics by 12.2% in the fourth quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock valued at $14,576,000 after purchasing an additional 278,700 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Voyager Therapeutics by 24.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company’s stock valued at $7,828,000 after purchasing an additional 275,571 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Voyager Therapeutics in the 4th quarter worth approximately $746,000. Finally, ADAR1 Capital Management LLC increased its holdings in shares of Voyager Therapeutics by 212.0% in the 4th quarter. ADAR1 Capital Management LLC now owns 126,792 shares of the company’s stock worth $719,000 after buying an additional 86,158 shares during the last quarter. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Price Performance

VYGR opened at $3.16 on Monday. Voyager Therapeutics has a fifty-two week low of $2.75 and a fifty-two week high of $9.55. The company’s 50 day moving average price is $3.74 and its two-hundred day moving average price is $5.30. The firm has a market capitalization of $174.45 million, a price-to-earnings ratio of 4.45 and a beta of 1.02.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). The company had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter last year, the business earned $1.25 earnings per share. As a group, equities research analysts predict that Voyager Therapeutics will post -0.91 EPS for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.